Mankind Pharma Limited — Results, 31-07-2025: Integrated Filing- Financial

Mankind Pharma has announced the consolidated financial results for the quarter ended June 30, 2025. The company's board met on July 31, 2025, and approved these results.

**Revenue Performance:** Total revenue from operations increased by 24.6% year-over-year (YoY) to ₹3,570.35 Cr. This growth largely reflects the inclusion of Bharat Serums and Vaccines Limited (BSV) following its acquisition in October 2024, making direct comparisons with the previous year less straightforward.

**Profitability and EPS:** Net profit attributable to equity holders declined by 17.6% YoY to ₹438.32 Cr. Basic EPS also saw a 20.0% drop, settling at ₹10.62. The operating margin slightly narrowed from 27.0% to 26.0%.

**Operational Costs:** A key driver behind the profit decline was a substantial increase in finance costs, which surged over 1500% YoY to ₹170.65 Cr. This significant rise is primarily due to the financing for the BSV acquisition. Employee benefits and depreciation expenses also increased.

**Balance Sheet / Cash Flow Health:** The company plans to raise up to ₹1,000 Cr in short-term funds through Commercial Papers, indicating ongoing capital requirements. An interim dividend of ₹1 per equity share has been declared.

**Management Commentary / Strategic Outlook:** The company is strategically consolidating its Women Health Rx portfolio by acquiring it from its wholly-owned subsidiary, BSV, a move aimed at enhancing operational and commercial synergies.

**Final Takeaway:** While Mankind Pharma shows strong top-line growth, the sharp increase in finance costs, largely tied to the BSV acquisition, has impacted profitability. Investors should monitor how the company integrates this major acquisition and manages its debt going forward.